The same surveillance initiative established for monitoring the initial and continued in vitro effectiveness of a new agent can also be designed to generate data critical to educating the medical world about any new product. Such studies are often run over several years and provide continuous and ongoing opportunities for education. IHMA’s experience in designing and conducting successful surveillance is unparalleled and encompasses every region in the world and any clinically relevant pathogen for which a product has been approved for use.